January 2020 Search Terms & Total Citations

PUBMED

MeSH Terms

- back pain
- chronic pain
- low back pain
- manipulation, osteopathic
- migraine disorders
- musculoskeletal pain
- neck pain
- osteopathic medicine

Text Word

- back pain
- chronic pain
- low back pain
- lower back pain
- migraine
- migraine disorders
- musculoskeletal
- musculoskeletal pain
- neck pain
- osteopathic manipulation
- osteopathic manipulative medicine
- osteopathic medicine
- osteopathy

Filters for Article Type

- randomized controlled trial
- controlled clinical trial
- clinical trial
- clinical study

COCHRANE & SCOPUS

Title, Abstract, Keyword Search Terms

- back pain
- chronic pain
- low back pain
- lower back pain
- migraine
- migraine disorders
- musculoskeletal pain
- neck pain
- osteopathic manual manipulation
- osteopathic manipulation
- osteopathic manipulative medicine
- osteopathic medicine
- osteopathy

Search Terms Used to Filter Article Type

- clinical trial
- controlled trial
- randomized controlled trial

EMBASE

Emtree Terms

- chronic pain
- low back pain
- migraine
- musculoskeletal pain
- neck pain
- osteopathic manipulation
- osteopathic medicine

General Terms

- back pain
- lower back pain
- osteopathic manipulative medicine
- osteopathic manual manipulation
- osteopathy

Filters for Article Type

- controlled clinical trial
- randomized controlled trial

JANUARY 2020



January 2020 Database Search Entries

PUBMED SEARCH ENTRY

((("musculoskeletal pain"[MeSH Terms] OR "musculoskeletal pain"[Text Word] OR "musculoskeletal"[Text Word] OR "migraine disorders"[MeSH Terms] OR "migraine disorders"[Text Word] OR "migraine"[Text Word] OR "neck pain"[MeSH Terms] OR "neck pain"[Text Word] OR "low back pain"[MeSH Terms] OR "low back pain"[Text Word] OR "lower back pain"[Text Word] OR "back pain"[MeSH Terms] OR "back pain"[Text Word] OR "chronic pain"[MeSH Terms] OR "chronic pain"[Text Word])))) **AND**

(("osteopathic medicine"[MeSH Terms] OR "osteopathic medicine"[Text Word] OR "osteopathic manipulative medicine"[Text Word] OR "osteopathy"[Text Word] OR "manipulation, osteopathic"[MeSH Terms] OR "osteopathic manipulation"[Text Word]))

(**Filters**: clinical study; clinical trial; controlled clinical trial; randomized controlled trial)

COCHRANE & SCOPUS SEARCH ENTRIES

(musculoskeletal pain OR migraine disorders OR migraine OR neck pain OR low back pain OR lower back pain OR back pain OR chronic pain) **AND**

(osteopathic medicine OR osteopathic manual manipulation OR osteopathic manipulative medicine OR osteopathy OR osteopathic manipulation) **AND**

(“randomized controlled trial” OR “clinical trial” OR “controlled trial”)

EMBASE SEARCH ENTRY

('musculoskeletal pain':ti,ab,kw OR migraine:ti,ab,kw OR 'neck pain':ti,ab,kw OR 'low back pain':ti,ab,kw OR 'lower back pain':ti,ab,kw OR 'back pain':ti,ab,kw OR chronic pain':ti,ab,kw) **AND**

('osteopathic medicine':ti,ab,kw OR 'osteopathic manual manipulation':ti,ab,kw OR 'osteopathic manipulative medicine':ti,ab,kw OR osteopathy:ti,ab,kw OR 'osteopathic manipulation':ti,ab,kw) **AND**

([controlled clinical trial]/lim OR [randomized controlled trial]/lim)

February 2020 Search Terms & Total Citations

PUBMED

MeSH Terms

- fibromyalgia
- headache disorders
- low back pain
- manipulation, osteopathic
- migraine disorders
- neck pain
- osteopathic medicine

All Fields

- chronic headache
- chronic low back pain
- chronic neck pain
- fibromyalgia
- headache disorders
- low back pain
- lower back pain
- migraine
- migraine disorders
- neck pain
- osteopathic manipulation
- osteopathic manipulative medicine
- osteopathic manipulative treatment
- osteopathic medicine

Filters for Article Type

- systematic review
- meta-analysis

COCHRANE & SCOPUS & WEB OF SCIENCE

Title, Abstract, Keyword Search Terms

- chronic headache
- chronic low back pain
- chronic lower back pain
- chronic neck pain
- chronic migraine
- fibromyalgia
- low back pain
- migraine
- migraine disorders
- neck pain
- OMT
- osteopathic manipulation
- osteopathic manipulative medicine
- osteopathic manipulative treatment
- osteopathic manual manipulation

Search Terms Used to Filter Article Type in Scopus & Web of Science

- systematic review
- meta-analysis

Filter for Article Type in Cochrane

- systematic review

EMBASE

Emtree Terms

- chronic headache
- chronic neck pain
- fibromyalgia
- low back pain
- migraine
- neck pain
- osteopathic manipulation

General Terms

- chronic low back pain
- chronic lower back pain
- chronic migraine
- OMT
- osteopathic manipulative medicine
- osteopathic manipulative treatment
- osteopathic manual manipulation

Filters for Article Type

- systematic review
- meta analysis

FEBRUARY 2020



February 2020 Database Search Entries

PUBMED SEARCH ENTRY	COCHRANE & SCOPUS & WEB OF SCIENCE SEARCH ENTRIES	EMBASE SEARCH ENTRY
(("low back pain"[MeSH Terms] OR "low back pain"[All Fields] OR "lower back pain"[All Fields] OR "chronic low back pain"[All Fields] OR "neck pain"[MeSH Terms] OR "neck pain"[All Fields] OR "chronic neck pain"[All Fields] OR "headache disorders"[MeSH Terms] OR "headache disorders"[All Fields] OR "chronic headache"[All Fields] OR "migraine disorders"[MeSH Terms] OR "migraine disorders"[All Fields] OR "migraine"[All Fields] OR "fibromyalgia" [MeSH Terms] OR "fibromyalgia"[All Fields])) **AND** ("osteopathic medicine"[MeSH Terms] OR "osteopathic medicine"[All Fields] OR "osteopathic manipulative medicine"[All Fields] OR "manipulation, osteopathic" [MeSH Terms] OR "osteopathic manipulation"[All Fields] OR "manipulation, osteopathic"[MeSH Terms] OR "osteopathic manipulative treatment" [All Fields]) (**Filters**: systematic reviews; meta-analysis)	low back pain OR chronic low back pain OR chronic lower back pain OR neck pain OR chronic neck pain OR chronic neck pain OR chronic headache OR chronic headache OR migraine OR chronic migraine OR fibromyalgia OR fibromyalgia) **AND** (osteopathic manipulative treatment OR osteopathic manipulative medicine OR osteopathic manipulation OR osteopathic manual manipulation OR OMT) **AND** (“systematic review" OR "meta analysis" OR "meta-analysis”)	('low back pain':ti,ab,kw OR 'chronic low back pain':ti,ab,kw OR 'chronic lower back pain':ti,ab,kw OR 'neck pain':ti,ab,kw OR 'chronic neck pain':ti,ab,kw OR migraine:ti,ab,kw OR 'chronic migraine':ti,ab,kw OR fibromyalgia:ti,ab,kw OR 'fibromyalgia':ti,ab,kw OR 'chronic headache':ti,ab,kw) **AND** ('osteopathic manual manipulation':ti,ab,kw OR 'osteopathic manipulative medicine':ti,ab,kw OR 'osteopathic manipulation':ti,ab,kw OR 'osteopathic manipulative treatment':ti,ab,kw) **AND** ([systematic review]/lim OR [meta analysis]/lim)

ClinicalTrials.gov Search Results 03/01/2020

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
1	NCT00520039	Osteopathic Otitis Media Research Study Study Documents:	Title Acronym: OOMRS Other Ids: KS5172007	Completed	•Otitis Media With Effusion	•Procedure: osteopathic manipulative medicine (OMM)	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Care Provider, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Change in Middle Ear Effusion Over Four Weeks Following an Episode of Acute Otitis Media •Change in Middle Ear Effusion Immediately After OMM at Study Visit 2 •Change in Middle Ear Effusion Immediately After OMM at Study Visit 3	Enrollment: 52 Age: 6 Months to 2 Years (Child) Sex: All	•West Virginia School of Osteopathic Medicine •University of New England •American Academy of Osteopathy •Osteopathic Research Center	•Other	Study Start: September 2007 Primary Completion: August 2009 Study Completion: August 2009 First Posted: August 23, 2007 Results First Posted: March 26, 2018 Last Update Posted: March 26, 2018	•University of New England College of Osteopathic Medicine, Biddeford, Maine, United States •West Virginia School of Osteopathic Medicine, Lewisburg, West Virginia, United States
2	NCT01020591	The Effect of Osteopathic Manual Therapy on Vascular Supply Study Documents:	Title Acronym: Other Ids: CDHA-RS/2010-227	Completed	•Knee Osteoarthritis	•Other: Osteopathic evaluation •Other: Osteopathic evaluation with treatment	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Resistive Index (RI) •The Knee Flexion Active Range of Motion, Balance and Pain (VAS)	Enrollment: 30 Age: 50 Years to 75 Years (Adult, Older Adult) Sex: All	•Nova Scotia Health Authority	•Other	Study Start: December 2009 Primary Completion: March 2010 Study Completion: March 2010 First Posted: November 25, 2009 Results First Posted: May 4, 2017 Last Update Posted: May 4, 2017	•Capital District Health Authority, Halifax, Nova Scotia, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
3	NCT03225599	Cranial Osteopathic Manipulative Medicine as an Adjunct Treatment for Concussion Study Documents:	Title Acronym: Other Ids: Concussion COMM	Completed	•Concussion Injury of Cerebrum •Cranial Osteopathic Medicine	•Other: Cranial Osteopathic Manipulative Medicine	Study Type: Interventional Phase: Not Applicable Study Design: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Change in Concussive Symptoms on the Post Concussion Symptom Scale	Enrollment: 9 Age: 14 Years and older (Child, Adult, Older Adult) Sex: All	•Northwell Health •University of Pittsburgh Medical Center	•Other	Study Start: February 9, 2010 Primary Completion: June 30, 2010 Study Completion: January 26, 2013 First Posted: July 21, 2017 Results First Posted: June 6, 2019 Last Update Posted: June 25, 2019	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
4	NCT00315120	Osteopathic Health Outcomes in Chronic Low Back Pain (OSTEOPATHIC) Trial Study Documents:	Title Acronym: Other Ids: •06-02-20-1 •K24AT002422	Completed	•Low Back Pain	•Procedure: A. Active OMT and active UST •Procedure: B. Sham OMT and active UST •Procedure: C. Active OMT and sham UST •Procedure: D. Sham OMT and sham UST	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Factorial Assignment •Masking: Double (Participant, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Change in Visual Analogue Scale Score for Pain Over 12 Weeks (OMT vs Sham OMT) •Change in Visual Analogue Scale Score for Pain Over 12 Weeks (Active UST vs Sham UST) •Roland Morris Disability Questionnaire (OMT and Sham OMT - Week 4) •Roland Morris Disability Questionnaire (OMT and Sham OMT - Week 8) •Roland Morris Disability Questionnaire (OMT and Sham OMT - Week 12) •Roland Morris Disability Questionnaire (UST and Sham UST - Week 4) •Roland Morris Disability Questionnaire (UST and Sham UST - Week 8) •Roland Morris Disability Questionnaire (UST and Sham UST - Week 12) •Medical Outcomes Study SF-36 Health Survey (OMT and Sham OMT - Week 4) •Medical Outcomes Study SF-36 Health Survey (OMT and Sham OMT - Week 8) •and 16 more	Enrollment: 455 Age: 21 Years to 69 Years (Adult, Older Adult) Sex: All	•University of North Texas Health Science Center •National Institutes of Health (NIH) •Osteopathic Heritage Foundations •National Center for Complementary and Integrative Health (NCCIH)	•Other •NIH	Study Start: August 2006 Primary Completion: January 2011 Study Completion: January 2011 First Posted: April 17, 2006 Results First Posted: July 6, 2016 Last Update Posted: July 6, 2016	•The Osteopathic Research Center, Fort Worth, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
5	NCT00637299	Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial Study Documents:	Title Acronym: Other Ids: 01/2008	Completed	•Chronic Obstructive Pulmonary Disease	•Other: Active osteopathic treatment (OMT +PR): Active Comparator •Other: sham osteopathic treatment (SOT +PR)	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Supportive Care Outcome Measures: •Walking Ability •Lung Function Test	Enrollment: 20 Age: 45 Years to 70 Years (Adult, Older Adult) Sex: All	•Fondazione Salvatore Maugeri	•Other	Study Start: January 2008 Primary Completion: July 2008 Study Completion: November 2008 First Posted: March 17, 2008 Results First Posted: April 20, 2009 Last Update Posted: October 24, 2011	•Fondazione Salvatore Maugeri, Montescano, Pavia, Italy
6	NCT01312233	Collaborative Care for Older Adults With Back Pain (COCOA) Study Documents:	Title Acronym: COCOA Other Ids: 5R18HP15126-02	Completed	•Low Back Pain	•Other: Medical Care •Other: Dual Care •Other: Shared Care	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Investigator) •Primary Purpose: Treatment Outcome Measures: •Change From Baseline in Patient-Rated Low Back Pain (LBP), an 11 Point Numerical Rating Scale (NRS) •Change From Baseline in Patient-Rated Disability, the 24-item Roland Morris Disability Questionnaire (RMDQ) •Veterans-RAND 36-item Short-Form Health Survey (VR-36) •Change From Baseline in Bothersomeness of Low Back Pain Symptoms •Patient Satisfaction With Care	Enrollment: 131 Age: 65 Years and older (Older Adult) Sex: All	•Palmer College of Chiropractic •Health Resources and Services Administration (HRSA) •Genesis Family Medical Center •University of Iowa •Thomas Jefferson University	•Other •U.S. Fed	Study Start: March 2011 Primary Completion: November 2012 Study Completion: March 2013 First Posted: March 10, 2011 Results First Posted: March 28, 2019 Last Update Posted: September 12, 2019	•Genesis Family Medical Center, Davenport, Iowa, United States •Palmer College of Chiropractic, Davenport, Iowa, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
7	NCT01190891	Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome Study Documents:	Title Acronym: Other Ids: 111411-1	Completed	•Shoulder Impingement Syndrome	•Procedure: Manual Physical Therapy •Procedure: Corticosteroid Injection	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Shoulder Pain and Disability Index •Global Rating of Change	Enrollment: 104 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Madigan Army Medical Center •University of Puget Sound •Franklin Pierce University	•U.S. Fed •Other	Study Start: May 2010 Primary Completion: March 2013 Study Completion: August 2013 First Posted: August 30, 2010 Results First Posted: April 29, 2016 Last Update Posted: April 29, 2016	•Madigan Army Medical Center, Tacoma, Washington, United States
8	NCT00423605	Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia. Study Documents:	Title Acronym: Other Ids: 06-010	Completed	•Fibromyalgia	•Drug: Xyrem®	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Number of Subjects Reporting Adverse Events	Enrollment: 560 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Jazz Pharmaceuticals	•Industry	Study Start: December 2006 Primary Completion: January 2010 Study Completion: January 2010 First Posted: January 18, 2007 Results First Posted: October 20, 2011 Last Update Posted: March 30, 2012	•Pinnacle Research Group, LLC, Anniston, Alabama, United States •Suncoast Internal Medicine Consultants, Auburn, Alabama, United States •Arizona Research Center, Phoenix, Arizona, United States •Advanced Clinical Research Institute, Anaheim, California, United States •Orange County Clinical Trials, Anaheim, California, United States •Northern California Research, Carmichael, California, United States •Med Investigations Inc., Fair Oaks, California, United States •Nerve Pro Research, Irvine, California, United States •Arroyo Medical Group, Inc., Pismo Beach, California, United States •AppleMed Research, Miami, Florida, United States •and 81 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
9	NCT00371137	A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia Study Documents:	Title Acronym: Other Ids: 06-008	Completed	•Fibromyalgia	•Drug: Xyrem® •Drug: Placebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF).	Enrollment: 548 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Jazz Pharmaceuticals	•Industry	Study Start: August 2006 Primary Completion: September 2008 Study Completion: December 2008 First Posted: September 1, 2006 Results First Posted: November 30, 2011 Last Update Posted: December 29, 2011	•Pinnacle Research Group, LLC, Anniston, Alabama, United States •Rheumatology Associates of N. AL, PC, Huntsville, Alabama, United States •Xenoscience, Inc. dba 21st Century Neurology, Phoenix, Arizona, United States •Arizona Research Center, Phoenix, Arizona, United States •Advanced Clinical Research Institute, Anaheim, California, United States •Providence Clinical Research, Burbank, California, United States •Northern California Research, Carmichael, California, United States •Pasadena Rehabilitation Institute, Pasadena, California, United States •Arroyo Medical Group, Pismo Beach, California, United States •Sacramento Research Medical Group, Sacramento, California, United States •and 60 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
10	NCT00507416	Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone Study Documents:	Title Acronym: UPFRONT Other Ids: C05009	Completed	•Multiple Myeloma	•Drug: Bortezomib •Drug: Dexamethasone •Drug: Melphalan •Drug: Prednisone •Drug: Thalidomide	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Progression Free Survival (PFS) •Percentage of Participants With an Overall Response •Percentage of Participants With a Complete Response •Percentage of Participants With a Complete Response or a Very Good Partial Response •Duration of Response •Overall Survival •Time to Alternative Therapy •Change From Baseline in EORTC QLQ-C30 - Global Health Status	Enrollment: 502 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Millennium Pharmaceuticals, Inc.	•Industry	Study Start: June 2007 Primary Completion: March 2013 Study Completion: March 2013 First Posted: July 26, 2007 Results First Posted: May 1, 2014 Last Update Posted: May 1, 2014	•Birmingham Hematology Oncology Associates, LLC, Birmingham, Alabama, United States •Desert Oasis Cancer Center, Casa Grande, Arizona, United States •Northern Arizona Hematology & Oncology Associates - AOA, Sedona, Arizona, United States •Arizona Oncology Associates, Tucson, Arizona, United States •Heritage Physician Group Oncology, Hot Springs, Arkansas, United States •Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States •Pacific Cancer Medical Centre, Anaheim, California, United States •Tower Cancer Research Foundation, Beverly Hills, California, United States •Compassionate Cancer Care Medical Group, Corona, California, United States •Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States •and 225 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
11	NCT00252564	Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer Study Documents:	Title Acronym: Other Ids: 05-041	Completed	•Metastatic Colorectal Cancer	•Drug: Bevacizumab •Drug: Oxaliplatin •Drug: Leucovorin •Drug: Fluorouracil •Drug: Cetuximab	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Progression-Free Survival (PFS) •Progression-free Survival (PFS) Rate at 1 Year. •Overall Survival (OS) •Objective Response Rate	Enrollment: 247 Age: 18 Years and older (Adult, Older Adult) Sex: All	•US Oncology Research •Bristol-Myers Squibb •Memorial Sloan Kettering Cancer Center •Prologue Research International	•Industry •Other	Study Start: September 2005 Primary Completion: June 2007 Study Completion: June 2009 First Posted: November 11, 2005 Results First Posted: March 14, 2011 Last Update Posted: February 15, 2019	•Brimingham Hematology and Oncology, Birmingham, Alabama, United States •Hematology Oncology Associates, Phoenix, Arizona, United States •Northern AZ Hematology & Oncology Assoc, Sedona, Arizona, United States •Business Office - ACRC, Tucson, Arizona, United States •Cancer Care Associates of Fresno Medical Group, Inc (aka California Cancer Care), Fresno, California, United States •Monterey Bay Oncology, Monterey, California, United States •Rocky Mountain Cancer Center-Midtown, Denver, Colorado, United States •Greeley Medical Clinic Oncology Hematology, PC, Greeley, Colorado, United States •Connecticut Oncology & Hematology, LLP, Torrington, Connecticut, United States •Integrated Community Oncology Network (ICON) / fka:Florida Oncology Associates, Jacksonville, Florida, United States •and 72 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
12	NCT00948766	Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Study Documents:	Title Acronym: ACTION Other Ids: CENA713DUS44	Completed	•Alzheimer's Disease	•Drug: Rivastigmine 4.6 mg/24 h (5 cm^2) •Drug: Rivastigmine 9.5 mg/24 h (10 cm^2) •Drug: Rivastigmine 13.3 mg/24 h (15 cm^2) •Drug: Placebo	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Core Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24 •Core Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24 •Core Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24 •Core Study: Change From Baseline in the Neuropsychiatric Inventory (NPI-12) Score at Week 24 •Extension Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24 •Extension Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24 •Extension Study: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Score at Week 24	Enrollment: 716 Age: 50 Years and older (Adult, Older Adult) Sex: All	•Novartis	•Industry	Study Start: July 2009 Primary Completion: January 2012 Study Completion: June 2012 First Posted: July 29, 2009 Results First Posted: February 11, 2013 Last Update Posted: August 28, 2013	•Clinical Research Advantage Inc./Neurological. Physicians of Arizona, Inc, Tempe, Arizona, United States •Northwest Neuro Specialist, PLLC, Tucson, Arizona, United States •IHS Research Center Inc., Conway, Arkansas, United States •East Bay Physicians Medical Group, Berkeley, California, United States •ATP Clinical Research, Inc., Costa Mesa, California, United States •Neuro Pain Medical Center, Fresno, California, United States •Margolin Brain Institute, Fresno, California, United States •Collaborative Neuroscience Network Inc., Garden Grove, California, United States •PCND Neuroscience Research Institute Inc./The Center for Memory and Aging, Poway, California, United States •Anderson Clinical Research, Redlands, California, United States •and 85 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
13	NCT01497938	Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature Study Documents:	Title Acronym: ASPIRE Other Ids: CEP 237	Completed	•Type 1 Diabetes	•Device: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature •Device: Medtronic (NO LGS FEATURE) using Paradigm® Revel™2.0 Pump	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Change in A1C From Baseline to End of Study Participation •The Event Area Under the Curve (AUC) Was Used to Demonstrate the Reduction of Nocturnal Hypoglycemia With the Low Glucose Suspend (LGS) Feature (LGS ON)	Enrollment: 247 Age: 16 Years to 70 Years (Child, Adult, Older Adult) Sex: All	•Medtronic Diabetes	•Industry	Study Start: December 2011 Primary Completion: June 2013 Study Completion: June 2013 First Posted: December 23, 2011 Results First Posted: March 17, 2014 Last Update Posted: March 17, 2014	•Arkansas Diabetes Clinic and Research Center, Little Rock, Arkansas, United States •AMCR Institute, Inc, Escondido, California, United States •Frank Diabetes Research Institute/ Mills-Peninsula Health Center, San Mateo, California, United States •University of Colorado Denver/ Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States •Metabolic Research Institute, West Palm Beach, Florida, United States •Atlanta Diabetes Associates, Atlanta, Georgia, United States •Physicians Research Associates, Lawrenceville, Georgia, United States •Endocrine Research Solutions, Roswell, Georgia, United States •Rocky Mountains Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States •Iowa Diabetes and Endocrinology Research Center, Des Moines, Iowa, United States •and 7 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
14	NCT00724711	Safety and Efficacy Study of Switching From Epzicom to Truvada Study Documents:	Title Acronym: SWIFT Other Ids: GS-US-164-0216	Completed	•HIV Infection	•Drug: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) •Drug: abacavir (ABC)/lamivudine (3TC)	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) < 200 Copies/ mL Through Week 48 Based on Time to Loss of Virologic Response (TLOVR) Algorithm •Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 200 Copies/ mL Through Week 48 •Percentage of Participants With Pure Virologic Response (PVR) for HIV-1 RNA Cutoff at 50 Copies/ mL Through Week 48 •Percentage of Participants With HIV-1 RNA < 200 Copies/mL at Week 48 •Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 •Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48 •Change From Baseline Calculated Creatinine Clearance (CLcr) Using Ideal Body Weight by Cockcroft-Gault Method at Week 48 •Change From Baseline Estimated Glomerular Filtration Rate (eGFR) by Modified Diet in Renal Disease (MDRD) at Week 48 •Change From Baseline Fasting Glucose at Week 48 •Change From Baseline Fasting Lipid Parameters at Week 48	Enrollment: 312 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Gilead Sciences	•Industry	Study Start: July 2008 Primary Completion: March 2011 Study Completion: April 2011 First Posted: July 29, 2008 Results First Posted: April 19, 2012 Last Update Posted: May 28, 2012	•Health For Life Clinic, PLLC, Little Rock, Arkansas, United States •Vista Medical Partners, Beverly Hills, California, United States •AHF, Beverly Hills, California, United States •Pacific Oaks Medical Group, Beverly Hills, California, United States •Center for Special Immunology, Fountain Valley, California, United States •Living Hope Clinical Foundation, Long Beach, California, United States •Jeffrey Goodman Special Care Clinic, Los Angeles, California, United States •Peter J. Ruane, MD, Inc., Los Angeles, California, United States •Anthony M Mills, MD, Los Angeles, California, United States •Orange Coast Medical Group, Newport Beach, California, United States •and 70 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
15	NCT00326898	Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Study Documents:	Title Acronym: ASSURE Other Ids: •NCI-2009-00534 •CAN-NCIC-E2805 •SWOG-E2805 •ECOG-E2805 •CDR0000478976 •CALGB-E2805 •E2805 •U10CA180820 •U10CA021115	Completed	•Clear Cell Renal Cell Carcinoma •Stage I Renal Cell Cancer AJCC v6 and v7 •Stage II Renal Cell Cancer AJCC v7 •Stage III Renal Cell Cancer AJCC v7	•Other: Laboratory Biomarker Analysis •Other: Placebo •Other: Quality-of-Life Assessment •Drug: Sorafenib Tosylate •Drug: Sunitinib Malate	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Disease-free Survival (DFS) •5-year Overall Survival Rate •Proportion of Patients With Cardiac Events •5-year Disease-free Survival (DFS) Rate Among Patients With Clear Cell Histology	Enrollment: 1943 Age: 18 Years and older (Adult, Older Adult) Sex: All	•National Cancer Institute (NCI) •Cancer and Leukemia Group B •NCIC Clinical Trials Group •Southwest Oncology Group	•NIH •Other	Study Start: April 24, 2006 Primary Completion: December 29, 2010 Study Completion: August 27, 2015 First Posted: May 17, 2006 Results First Posted: December 12, 2016 Last Update Posted: June 11, 2019	•University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States •Clearview Cancer Institute, Huntsville, Alabama, United States •Mobile Infirmary Medical Center, Mobile, Alabama, United States •Providence Hospital, Mobile, Alabama, United States •University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States •Providence Alaska Medical Center, Anchorage, Alaska, United States •Fairbanks Memorial Hospital, Fairbanks, Alaska, United States •Banner Thunderbird Medical Center, Glendale, Arizona, United States •Banner-University Medical Center Phoenix, Phoenix, Arizona, United States •Western Regional CCOP, Phoenix, Arizona, United States •and 977 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
16	NCT01358526	Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain Study Documents:	Title Acronym: Other Ids: ONU3701	Completed	•Low Back Pain	•Drug: Oxycodone/ Naloxone Controlled-release •Drug: Placebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •The "Average Pain Over the Last 24 Hours" at Week 12 of the Double-blind Period •The Sleep Disturbance Subscale of the MOS Sleep Scale at Weeks 4, 8, and 12 •Patient Global Impression of Change (PGIC)	Enrollment: 1095 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Purdue Pharma LP	•Industry	Study Start: May 2011 Primary Completion: October 2012 Study Completion: November 2012 First Posted: May 23, 2011 Results First Posted: September 3, 2014 Last Update Posted: November 11, 2015	•Alabama Orthopaedic Center, PC, Birmingham, Alabama, United States •Alliance Clinical Research, Birmingham, Alabama, United States •Winston Technology Research, LLC, Haleyville, Alabama, United States •Monte Sano Clinical Research, LLC, Huntsville, Alabama, United States •Research Facility, Mobile, Alabama, United States •Radiant Research, Inc., Chandler, Arizona, United States •Dedicated Clinical Research, Phoenix, Arizona, United States •Arizona Research Center, Phoenix, Arizona, United States •Clinical Research Advantage, Inc./Tatum Highlands Medical Associates, PLLC, Phoenix, Arizona, United States •Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States •and 141 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
17	NCT00640926	Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia Study Documents:	Title Acronym: Other Ids: RX-1741-201	Completed	•Community-Acquired Pneumonia (CAP)	•Drug: Radezolid	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC)	Enrollment: 158 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•Melinta Therapeutics, Inc.	•Industry	Study Start: October 2007 Primary Completion: March 2009 Study Completion: April 2009 First Posted: March 21, 2008 Results First Posted: February 4, 2010 Last Update Posted: May 12, 2016	•eStudySite, San Diego, California, United States •Olive View- UCLA Center, Dept. Emergency Medicine, Sylmar, California, United States •Wayne State University School of Medicine/Detroit Receiving Hospital, Detroit, Michigan, United States •Arnold Markowitz, MD, Keego Harbor, Michigan, United States •Mercury Street Medical Group, LLC, Butte, Montana, United States •Dr. John Bernard, Belvidere, New Jersey, United States •University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine (UMDNJ-SOM), Cherry Hill, New Jersey, United States •Warminster Medical Associates, P.C., Warminster, Pennsylvania, United States •Ronald Collette, MD, Burnaby, British Columbia, Canada •The Medical Arts Health Research Group, Kelowna, British Columbia, Canada •and 20 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
18	NCT00050960	Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Study Documents:	Title Acronym: Other Ids: L1069-48	Completed	•Non-small Cell Lung Cancer	•Drug: bexarotene with carboplatin and paclitaxel •Drug: carboplatin and paclitaxel	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Overall Survival	Enrollment: 612 Age: Child, Adult, Older Adult Sex: All	•Eisai Inc.	•Industry	Study Start: May 2002 Primary Completion: July 2004 Study Completion: March 2005 First Posted: January 3, 2003 Results First Posted: August 24, 2010 Last Update Posted: July 13, 2012	•Montgomery Cancer Center, L.L.C., Montgomery, Alabama, United States •Arizona Clinical Research Center, Inc., Tucson, Arizona, United States •Bay Area Cancer Research Group, LLC, Concord, California, United States •Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States •Pacific Coast Hematology/ Oncology Medical Group, Inc., Fountain Valley, California, United States •California Cancer Care, Inc., Greenbrae, California, United States •Coast Hematology and Oncology Associates, Long Beach, California, United States •Metropolitan Hematology/ Oncology Medical Group, Los Angeles, California, United States •Sant P. Chawla, Inc., Los Angeles, California, United States •UCLA Medical Center, Los Angeles, California, United States •and 144 more